| 9.1 -0.35 (-3.7%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 13.26 |
1-year : | 15.38 |
| Resists | First : | 11.36 |
Second : | 13.17 |
| Pivot price | 10.61 |
|||
| Supports | First : | 8.43 |
Second : | 7.01 |
| MAs | MA(5) : | 9.79 |
MA(20) : | 10.34 |
| MA(100) : | 6.72  |
MA(250) : | 7.31 |
|
| MACD | MACD : | 0 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 16.1 |
D(3) : | 20.4 |
| RSI | RSI(14): 40.8 |
|||
| 52-week | High : | 15.21 | Low : | 1.75 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ARQT ] has closed above bottom band by 17.3%. Bollinger Bands are 73.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.46 - 9.52 | 9.52 - 9.58 |
| Low: | 8.32 - 8.38 | 8.38 - 8.43 |
| Close: | 9.01 - 9.11 | 9.11 - 9.19 |
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Thu, 18 Apr 2024
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 4.2% - MarketBeat
Tue, 16 Apr 2024
DekaBank Deutsche Girozentrale Acquires Shares of 140,000 Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Wed, 10 Apr 2024
Arcutis Biotherapeutics Welcomes New CFO David Topper - TipRanks.com - TipRanks
Tue, 19 Mar 2024
Arcutis Biotherapeutics, Inc. (ARQT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Mon, 18 Mar 2024
Wall Street Analysts See a 54.78% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High? - Yahoo Finance
Sun, 03 Mar 2024
Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 115 (M) |
| Shares Float | 75 (M) |
| Held by Insiders | 2.4 (%) |
| Held by Institutions | 95.8 (%) |
| Shares Short | 19,260 (K) |
| Shares Short P.Month | 15,780 (K) |
| EPS | -3.78 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.92 |
| Profit Margin | 0 % |
| Operating Margin | -452.3 % |
| Return on Assets (ttm) | -38.2 % |
| Return on Equity (ttm) | -175.8 % |
| Qtrly Rev. Growth | 356.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.51 |
| EBITDA (p.s.) | -2.09 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -247 (M) |
| Levered Free Cash Flow | -151 (M) |
| PE Ratio | -2.41 |
| PEG Ratio | -0.5 |
| Price to Book value | 9.89 |
| Price to Sales | 17.55 |
| Price to Cash Flow | -4.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|